$28.19
-2.81-9.06%
Last update: Nov 10, 6:24 PM
Ionis Pharmaceuticals Inc
IONSNASDAQ
Ionis Pharmaceuticals fell 55.4% from $69.54 to $31.00, behind the S&P 500's +10.0%. Its worst day was Jul 9 (−23.9%), and its low came Nov 9 at $31.00.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Ionis Pharmaceuticals closed at its highest level of the year, 24.4% above where the year started.
+3.6% · S&P 500 +1.9%
EPS of $-1.15 beat the $-1.26 estimate on $203.0M revenue (est. $155.9M); FY revenue guidance of $800.0M–$825.0M against the $895.6M consensus.
Story events cover the past 12 months · Times ET
−5.3% · S&P 500 +0.8%
EPS of $-0.30 beat the $-0.80 estimate on $246.0M revenue (est. $194.9M); FY revenue guidance of $875.0M–$900.0M against the $816.3M consensus.
+4.2% · S&P 500 0.0%
Ionis Pharmaceuticals shares fell 23.9%, while the S&P 500 rose 0.8%.
−23.9%, the year's worst day, on 20M shares, the year's heaviest volume · S&P 500 +0.8%
EPS of $-0.42 beat the $-0.95 estimate on $268.0M revenue (est. $189.6M); FY revenue guidance of $875.0M–$900.0M against the $889.0M consensus.
−2.3% · S&P 500 −1.5%
Ionis Pharmaceuticals shares fell 8.1%, while the S&P 500 fell 0.5%.
−8.1% · S&P 500 −0.5%
EPS of $-0.40 beat the $-0.99 estimate on $243.0M revenue (est. $183.3M); FY revenue guidance of $875.0M–$900.0M against the $920.8M consensus.
−21.4% · S&P 500 +2.4%
Where it ended: a close of $31.00 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 24, 2027 (EPS est. $-1.00, revenue est. $223.6M).
Nothing in the past 12 months.
All IONS dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IONS and SPY from Benzinga historical bars. Not investment advice.
